Women's voices in the menopause: results from an international survey on vaginal atrophy.

Maturitas

Research Center for Reproductive Medicine, Department of Morphological, Eidological and Clinical Sciences, University of Pavia, Pavia, Italy.

Published: November 2010

AI Article Synopsis

  • The study surveyed 4,246 postmenopausal women aged 55-65 across five countries to understand the prevalence and impact of vaginal atrophy.
  • About 39% of participants reported experiencing vaginal atrophy, with varying prevalence rates among countries, and differing attitudes towards its symptoms and treatment options.
  • Many women were unaware of local treatment options, highlighting the need for tailored approaches in addressing the concerns of menopausal women in different regions.

Article Abstract

Objectives: To consider issues relating to vaginal atrophy via an international survey.

Methods: Using a structured questionnaire, interviews were performed on 4246 women aged 55-65 years living in Sweden, Finland, the United Kingdom, the United States and Canada.

Results: Overall, 98% of survey respondents were postmenopausal. Thirty-nine percent of the postmenopausal women had experienced vaginal atrophy, with the prevalence varying between countries, from 34% in Canada to 43% in Finland and the United States. Attitudes towards symptoms also varied between countries. Symptoms were described as moderate or severe by less than half of women from Finland and Sweden, compared with nearly two-thirds of women from the United States. However, vaginal atrophy was deemed to impact on quality of life by a higher proportion of women in Finland and Sweden (≥60%) than in the United Kingdom, the United States and Canada (≤50%). Overall, 77% of respondents believed women were uncomfortable discussing vaginal atrophy and 42% did not know that local treatment was available. The proportions of women unaware of the availability of local treatment were higher in the United States, the United Kingdom and Canada (51%, 50% and 48%, respectively), and very low in Finland (10%). Whilst 63% of women who had experienced vaginal atrophy had never been prescribed treatment for the condition, 67% of those who had been treated reported positive effects.

Conclusion: The survey results illustrate differing needs of menopausal women in different countries. Country-specific approaches may be required to improve the uptake of treatment for vaginal atrophy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.maturitas.2010.08.001DOI Listing

Publication Analysis

Top Keywords

vaginal atrophy
28
united states
20
united kingdom
12
women
9
united
8
finland united
8
kingdom united
8
women experienced
8
experienced vaginal
8
women finland
8

Similar Publications

Female sexual dysfunction is highly prevalent among postmenopausal females approaching 50%, with vulvovaginal atrophy (VVA) being a cardinal sign. For decades, hormone replacement therapy was the only solution to relieve symptoms associated with this atrophy. However, it was limited by its serious side effects, raising the need for new treatment strategies.

View Article and Find Full Text PDF

: This is a prospective study. Atrophic vulvovaginitis (VVA), a prevalent condition resulting from estrogen deficiency after the menopause, is characterized by symptoms such as vaginal dryness, itching, burning, dyspareunia, and urinary discomfort. Standard treatment involves systemic estrogen replacement therapy (HRT) and localized estrogen treatments, such as estriol.

View Article and Find Full Text PDF

Optimizing the regenerative potential of vaginal fibroblasts: The role of autologous platelet-rich plasma and hyaluronic acid in vitro.

Maturitas

January 2025

Faculty of Medicine, Geneva University, 1205 Geneva, Switzerland; Department of Pediatrics, Gynecology and Obstetrics, Division of Gynecology, Urogynecology Unit, Geneva University Hospitals, Geneva, Switzerland. Electronic address:

Objective: Many postmenopausal women suffering from vulvovaginal atrophy are looking for non-hormonal treatments. Platelet-rich plasma (PRP) therapy has emerged as a novel and promising approach for gynecological applications. PRP is an autologous blood product rich in growth factors used to stimulate tissue regeneration.

View Article and Find Full Text PDF

Background: Lasofoxifene, a novel endocrine therapy (ET), showed antitumor activity versus fulvestrant in women with ESR1-mutated, metastatic breast cancer (mBC) that progressed on prior ET (phase 2, ELAINE 1 study). We investigated changes in genitourinary syndrome of menopause (GSM) vulvar-vaginal symptoms with lasofoxifene and how patient/disease characteristics affect baseline vulvar-vaginal symptoms in ELAINE 1.

Methods: Women were randomized to oral lasofoxifene 5 mg/day or IM fulvestrant 500 mg (days 1, 15, and 29, then every 28 days) until disease progression/severe toxicity.

View Article and Find Full Text PDF

Genitourinary syndrome of menopause (GSM) is a common complication secondary to estrogen depletion which leads to tissue changes in the female genitourinary tract. Here, we sought to investigate the short- and long-term effects of CO laser therapy on symptoms of GSM in postmenopausal women. In this clinical trial, 47 postmenopausal women with symptoms of GSM were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!